Book a Meeting

Anti-CD40 Ligand Antibody, Non-Fucosylated (BioBet-669ZP) (CAT#: BioBet-669ZP) Datasheet

Target
CD40 Ligand
Isotype
IgG
Description
ADCC-Enhanced anti-CD40 Ligand (ABI793) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Acute tubular necrosis; Decrease in platelet numbers
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 Ligand antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40LG
Full Name
CD40 ligand
Background
The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome.
Alternative Names
CD40LG; CD40 ligand; IGM; IMD3; TRAP; gp39; CD154; CD40L; HIGM1; T-BAM; TNFSF5; hCD40L; CD40-L; CD40 antigen ligand; T-cell antigen Gp39; T-B cell-activating molecule; TNF-related activation protein; tumor necrosis factor (ligand) superfamily member 5
Gene ID
959
UniProt ID
Q5ZPR3
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Immunodeficiency With Hyper-Igm, Type 1.
Related Pathways
Its related pathways are Transcriptional misregulation in cancer and NF-KappaB Family Pathway.
Function
Receptor for TNFSF5/CD40LG (PubMed:31331973). Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity).
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody
Post-translational modifications
1.Glycosylation at Asn153 and Asn180 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
ABI793
Host
Human
Species Reactivity
Human
Description
ABI793 is a novel human anti-human CD154 mAb, was derived from a hybridoma generated after immunization of human immunoglobulin transgenic mice. ABI793 treatment was associated with episodes of severe acute tubular necrosis and a decrease in platelet numbers. Chronic and acute thromboembolic vascular lesions with hemorrhages were observed in the lung and brain of two allograft recipients. None of these side effects were observed in animals that underwent autotransplantation, thus excluding direct toxicity of ABI793.
Antibody Indication
Acute tubular necrosis; Decrease in platelet numbers

Acute tubular necrosis; Decrease in platelet numbers

Related Products

Anti-CD40 ligand Antibody, Non-Fucosylated (BioBet-150ZP) (CAT#: BioBet-150ZP)
Anti-CD40 ligand Antibody, Highly Galactosylated (BioBet-GA-150ZP) (CAT#: BioBet-GA-150ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.